Updated: Sep 21
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching hepatocellular carcinoma may encounter central memory T-lymphocyte therapy as an emerging cancer immunotherapy option. In China, this therapy is available through Le City licensed medical-access pathways in Hainan, subject to medical evaluation and the applicable regulatory requirements. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing hepatocellular carcinoma immunotherapy China.
Key Takeaways |
|
What Is Central Memory T-Lymphocyte Therapy?
Central Memory T-Lymphocyte Therapy is an autologous immune cell therapy developed using the biological characteristics of central memory T cells (Tcm). The product associated with this treatment is SDT-T001, developed by Sedart Biopharmaceutical Co., Ltd.
The treatment uses the patient's own immune cells. After preparation and reinfusion, the cells are designed to home in on liver cancer lesions and participate in ongoing immune surveillance against residual tumor cells. The intended concept is that central memory T cells can maintain longer-lasting immune activity after reinfusion.
For patients researching hepatocellular carcinoma immunotherapy China, it is important to distinguish the treatment concept from proven clinical outcomes. Efficacy and safety remain under evaluation, and the available treatment status does not establish that the therapy is a cure or that it will provide a particular outcome for an individual patient.
Is Central Memory T-Lymphocyte Therapy Available in China?
Yes. Central Memory T-Lymphocyte Therapy is available through licensed use in the Le City medical-access pathway in Hainan, subject to the applicable medical and regulatory requirements.
The treatment has a moderate- to high-risk regulatory classification, and its efficacy and safety remain under evaluation. This access pathway is specific to the designated medical setting and should not be interpreted as nationwide approval for hepatocellular carcinoma immunotherapy China.
Patients considering treatment should confirm current availability, medical requirements, and the applicable access process with the treating hospital before making travel arrangements.
Where Is the Treatment Offered?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University).
Technical support is provided by Sedart Biopharmaceutical Co., Ltd., and the associated product is SDT-T001, an autologous immune cell therapy developed based on the biological characteristics of central memory T cells.
Who May Be Eligible?
The identified indication is hepatocellular carcinoma (liver cell carcinoma). Detailed individual eligibility criteria are not specified beyond the indication.
The available treatment information also states that efficacy and safety remain under evaluation and that access is subject to clinical research and Le City licensed use. Patients therefore need an individual medical assessment before treatment can be considered.
Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does It Cost?
The estimated cost is ¥120,000 (approximately US$17,700) per session. The USD estimate uses an exchange rate of approximately ¥6.78 per US$1 as a reference for September 4, 2026.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, medication, or travel expenses. Confirm final pricing and the full scope of costs directly with the hospital before arranging treatment.
Why International Patients May Consider This Option
For some international patients researching hepatocellular carcinoma immunotherapy China, a licensed treatment pathway that is not broadly accessible in their home country may be worth discussing with a qualified specialist.
China's Le City pathway provides a regulated medical setting through which eligible patients can explore certain therapies that have a specific access status. However, availability should be evaluated separately from evidence of effectiveness. Central Memory T-Lymphocyte Therapy remains subject to ongoing evaluation of safety and efficacy, so patients should discuss potential benefits, risks, alternatives, and the available evidence directly with qualified physicians.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and hepatocellular carcinoma-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering Hepatocellular Carcinoma Immunotherapy China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is central memory T-lymphocyte therapy available for hepatocellular carcinoma in China?
Yes. The therapy is available through Le City licensed use in Hainan at Hainan Haikong Le City Hospital, subject to medical evaluation and applicable requirements.
How much does hepatocellular carcinoma immunotherapy cost in China?
The estimated cost is ¥120,000 (approximately US$17,700) per session. Patients should confirm the final price and what it includes directly with the hospital.
Who may qualify for central memory T-lymphocyte therapy?
Hepatocellular carcinoma is the identified indication, but detailed individual eligibility criteria are not specified. Final eligibility requires assessment by the treating medical team.
Is central memory T-lymphocyte therapy approved throughout China?
No nationwide approval should be inferred from Le City licensed use. The treatment has a specific access pathway in Hainan, while its efficacy and safety remain under evaluation.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.